These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 30312438)

  • 21. Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?
    Gross P; Schirutschke H; Paliege A
    Nephrol Dial Transplant; 2019 Jan; 34(1):35-37. PubMed ID: 30312449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA
    Drugs; 2019 Feb; 79(3):303-313. PubMed ID: 30689194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Dandurand A; Ouyang J; Czerwiec FS; Blais JD;
    Nephrol Dial Transplant; 2018 Mar; 33(3):477-489. PubMed ID: 28379536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
    Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
    Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.
    Mader G; Mladsi D; Sanon M; Purser M; Barnett CL; Oberdhan D; Watnick T; Seliger S
    BMC Nephrol; 2022 Oct; 23(1):334. PubMed ID: 36258169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
    Xie X; Cai Q; Guo XY; Bai DH; Sheng HZ; Wang BK; Yan K; Lu AM; Wang XR
    Comb Chem High Throughput Screen; 2020; 23(1):6-16. PubMed ID: 31793415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice.
    Hines CB; Hooper GL; Collins-Yoder A
    Nephrol Nurs J; 2020; 47(2):145-150. PubMed ID: 32343088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
    Zhou JX; Torres VE
    Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
    Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Koch G; Ouyang J; McQuade RD; Blais JD; Czerwiec FS; Sergeyeva O;
    N Engl J Med; 2017 Nov; 377(20):1930-1942. PubMed ID: 29105594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
    Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
    Li X; Li W; Li Y; Dong C; Zhu P
    Nefrologia (Engl Ed); 2023; 43(6):731-741. PubMed ID: 37150675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
    Kramers BJ; Koorevaar IW; van Gastel MDA; van Goor H; Hallows KR; Heerspink HL; Li H; Leonhard WN; Peters DJM; Qiu J; Touw DJ; Gansevoort RT; Meijer E
    Clin J Am Soc Nephrol; 2022 Apr; 17(4):507-517. PubMed ID: 35314480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression.
    Quiroga B; Torra R
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.
    Capuano I; Buonanno P; Riccio E; Rizzo M; Pisani A
    Clin Nephrol; 2022 Mar; 97(3):131-140. PubMed ID: 34846296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.
    Uchiyama K; Kitayama C; Yanai A; Ishibashi Y
    Sci Rep; 2021 Sep; 11(1):17666. PubMed ID: 34480075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O; Chapman AB; Gansevoort RT; Higashihara E; Perrone RD; Torres VE; Blais JD; Zhou W; Ouyang J; Czerwiec FS
    J Am Soc Nephrol; 2017 May; 28(5):1592-1602. PubMed ID: 27920153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment.
    Lee Y; Blount KL; Dai F; Thompson S; Scher JK; Bitterman S; Droher M; Herzog EL; Moeckel G; Karihaloo A; Dahl NK
    Clin Exp Nephrol; 2018 Aug; 22(4):906-916. PubMed ID: 29453607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.